VJHemOnc Podcast

The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and showcased the latest advances in the field of transplantation and cellular therapies.

VJHemOnc is joined by Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, who chaired an insightful discussion on the main takeaways from the EBMT 2021 meeting, including trial updates in conditioning, novel approaches to managing graft-versus-host disease, the role of transplantation in rarer hematological malignancies and the latest news in immune effector cell therapies.

In this roundtable discussion, Prof. Chabannon is joined by Nico Gagelmann, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zinaida Perić, MD, PhD, of the University Hospital Centre Zagreb, School of Medicine, Zagreb, Croatia and Eolia Brissot, MD, of Saint-Antoine Hospital, Paris, France.

The post The Post-EBMT VJSessions from VJHemOnc appeared first on VJHemOnc.

Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be diagnosed per year in the US alone. According to the NIH, 27.4% of people diagnosed with AML will survive for five years or more. AML is typically treated with a combination of cytarabine and anthracycline-based chemotherapy regimens, and allogeneic stem cell transplantation in eligible patients, however, many patients will relapse after transplantation and many cannot withstand intensive chemotherapy. The identification of mutations such as FLT3-ITD, NMP1 and CEBPA has improved risk-stratification and treatment optimization, and novel post-transplant maintenance therapies are showing promise in improving outcomes for patients with AML.

In this podcast, Guillermo Sanz of the University Hospital La Fe, Valencia, Spain, Nico Gagelmann of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Mohamad Mohty of Saint-Antoine Hospital, Paris, France, and Farhad Ravandi, of the University of Texas MD Anderson Cancer Center, Houston, TX, share updates on their research in the field of AML which they presented at the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

The post Post-EBMT highlights in acute myeloid leukemia appeared first on VJHemOnc.

Chronic lymphocytic leukemia (CLL), also known as B-cell CLL (B-CLL) is the most common leukemia in Europe and North America. CLL progresses slowly and is generally incurable, with the majority of patients showing relapse and having short remissions. Over the past decade, there has been a dramatic increase in our understanding of the pathogenesis of CLL, which has led to the development of small molecule inhibitors and multiple molecular inhibitors treating CLL which target the B-cell receptor pathway and BCL2. Smaller studies of chimeric antigen receptor (CAR) T-cell therapies have also shown promising results, although longer-term follow-up and larger trials are required.

Although the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition (ASH 2020) was held virtually, due to the ongoing COVID-19 pandemic, the quality and reach of presentations remained truly spectacular.

In this roundtable discussion, John Gribben, MD, DSc, FRCP, FRCPath, FMedSci, Barts Cancer Institute, London, UK, Alessandra Tedeschi, MD, Niguarda Cancer Center, Milan, Italy, Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, debate the key updates in the field of CLL presented at ASH 2020.

The post The CLL Sessions: highlights from ASH 2020 appeared first on VJHemOnc.

Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for lymphoma are not yet well-characterized and treatment depends on the type of lymphoma, it’s location and stage. Recent developments in the treatment of lymphoma include research into novel chemotherapy regimens, chimeric antigen receptor (CAR) T-cell therapies, antibody-drug conjugates and checkpoint inhibitors, with some therapies alreadyapproved and many being tested in clinical trials.

In 2020, the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2020) was presented as an all-virtual event due to the COVID-19pandemic, however this did not detract from the excellence and quality of data and research presented.

In this roundtable discussion, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, and Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discuss the hottest topics in the treatment of lymphoma presented at ASH 2020.

The post The Lymphoma Sessions: highlights from ASH 2020 appeared first on VJHemOnc.

The diagnosis and treatment of myelodysplastic syndromes (MDS) has moved on dramatically in the few three decades. From across the globe, pioneers in the recognition and understanding of MDS pulled together to collaborate and push forward this research laying the foundations of where we are today.

VJHemOnc were delighted to catch up with four of these pioneers to discuss their research – taking us from inception to future outlooks. Chaired by Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, this roundtable discussion included a prestigious panel in the world of MDS – Ghulam Mufti, OBE, DM, FRCP, FRCPath, King’s College London, London, Peter Greenberg, MD, Stanford University Medical Center, Stanford, CA, Mario Cazzola, MD, University of Pavia, Italy and John M. Bennett, MD, University of Rochester Medical Center, Rochester, NY.

The post The MDS Sessions: Giants in MDS appeared first on VJHemOnc.